Dashboard
Weak Long Term Fundamental Strength with a -19.19% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.68 times
- The company has been able to generate a Return on Equity (avg) of 5.54% signifying low profitability per unit of shareholders funds
Flat results in Sep 26
Stock is technically in a Mildly Bullish range
With ROCE of 5.7, it has a Attractive valuation with a 1.9 Enterprise value to Capital Employed
Falling Participation by Institutional Investors
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,743 Cr (Small Cap)
38.00
40
0.27%
0.52
6.03%
2.31
Total Returns (Price + Dividend) 
Latest dividend: 0.4 per share ex-dividend date: Sep-04-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Hikal Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Following a recent upgrade in its Mojo Grade from Sell to Hold, the stock’s price action and technical parameters suggest a cautiously optimistic outlook amid mixed market signals.
Read More
Hikal Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial and Technical Signals
Hikal Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement in its technical indicators and valuation metrics despite ongoing challenges in financial performance and long-term fundamentals. The upgrade, effective from 18 Nov 2026, is driven primarily by a bullish shift in technical trends and an attractive valuation profile relative to peers, offsetting concerns over weak profitability and institutional participation.
Read More
Hikal Ltd Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Market Returns
Hikal Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend as of November 2026. This change is underscored by improvements in key indicators such as the MACD and moving averages, despite some mixed signals from other oscillators. The company’s stock price has gained 2.48% on the day, reflecting renewed investor interest amid a complex technical backdrop.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
05-Nov-2026 | Source : BSETranscript of Earnings Call for the Quarter and half year ended September 30 2026.
Announcement under Regulation 30 (LODR)-Newspaper Publication
04-Nov-2026 | Source : BSEPursuant to Regulation 30 and 47 of the SEBI LODR Regulations- Intimation of Newspaper Publication of Financial Results Q2 FY 27
Announcement under Regulation 30 (LODR)-Press Release / Media Release
03-Nov-2026 | Source : BSEAnnouncement under Regulation 30 of SEBI LODR 2015- Press Release on the results of the Company for the quarter and half year ended September 30 2026.
Corporate Actions 
No Upcoming Board Meetings
Hikal Ltd has declared 20% dividend, ex-date: 04 Sep 26
Hikal Ltd has announced 2:10 stock split, ex-date: 27 Feb 15
Hikal Ltd has announced 1:2 bonus issue, ex-date: 22 Jun 18
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 4 Schemes (5.09%)
Held by 37 FIIs (1.27%)
Kalyani Investment Company Limited (31.36%)
Tata Mutual Fund - Tata Small Cap Fund (2.68%)
19.3%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 7.80% vs -22.45% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 17.57% vs -151.39% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -18.70% vs 4.47% in Sep 2024
Growth in half year ended Sep 2025 is -344.87% vs 20.06% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -8.73% vs 2.91% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -255.67% vs 14.08% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -7.91% vs 4.21% in Mar 2025
YoY Growth in year ended Mar 2026 is -153.74% vs 30.46% in Mar 2025